This observational, prospective, multicenter study will evaluate the efficacy and safety of MabThera/Rituxan in patients with active rheumatoid arthritis and an inadequate response or intolerance to one anti-TNF therapy. Patients who receive MabThera/Rituxan according to the current standard and in line with the summary of product characteristics at a dose of 1000 mg intravenously on Days 1 and 15 will be followed for 20 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01641952?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
